Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screeningDrug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancerAn organoid platform for ovarian cancer captures intra- and interpatient heterogeneityStructure-guided design of selective Epac1 and Epac2 agonists
author
nationality
type
label
Johannes L Bos
firstName
Johannes L